Tucker Madeline, Padarti Akhil
Neurology, University of South Alabama College of Medicine, Mobile, USA.
Cureus. 2021 Oct 13;13(10):e18757. doi: 10.7759/cureus.18757. eCollection 2021 Oct.
Direct oral anticoagulants (DOACs) are becoming increasingly prevalent in the general population for anticoagulation. However, rare adverse effects from these medications are still being discovered. Thrombocytopenia has previously been reported with these medications, but its clinical significance is still unknown. We present a patient who developed thrombocytopenia from apixaban and who subsequently developed a severe presentation of heparin-induced thrombocytopenia (HIT) from enoxaparin. This raises the possibility that thrombocytopenia from oral anticoagulants increases the likelihood of the development of heparin-induced thrombocytopenia.
直接口服抗凝剂（DOACs）在普通人群中用于抗凝的情况越来越普遍。然而，这些药物罕见的不良反应仍在不断被发现。此前已有关于这些药物导致血小板减少症的报道，但其临床意义仍不明确。我们报告了一名因阿哌沙班出现血小板减少症，随后又因依诺肝素出现严重肝素诱导的血小板减少症（HIT）表现的患者。这增加了口服抗凝剂所致血小板减少症会增加肝素诱导的血小板减少症发生可能性的可能性。
